Humphrey G B, Blackstock R, Falletta J M, Metzgar R S, Richie E R, Pullen D J, Boyett J M, Shuster J J, Roper M A, Russell E C
Cancer. 1985 Oct 15;56(8):1995-2000. doi: 10.1002/1097-0142(19851015)56:8<1995::aid-cncr2820560818>3.0.co;2-2.
The presence or absence of the Fc receptor (FcR) on bone marrow lymphoblasts was evaluated in 279 cases of acute lymphoblastic leukemia (ALL) by member institutions of the Pediatric Oncology Group (POG). The case material was classified as follows: 19 cases of positive (greater than or equal to 20% +), 24 additional cases as intermediate (greater than or equal to 10% but less than 20%), and the remaining 236 cases as negative (less than 10%). Intermediate and positive cases were relatively equally distributed between null cell leukemia and pre-B-cell leukemia, and there were one intermediate and two positive T-cell cases. One of two cases of B-cell leukemia was also positive. There were no distinguishing clinical or laboratory characteristics which distinguished the FcR+ cases, nor was the FcR of prognostic significance within ALL as a group or within immunologically defined phenotypes.
儿科肿瘤学组（POG）的成员机构对279例急性淋巴细胞白血病（ALL）患者的骨髓淋巴母细胞上Fc受体（FcR）的存在与否进行了评估。病例材料分类如下：19例阳性（≥20% +），另外24例为中间型（≥10%但＜20%），其余236例为阴性（＜10%）。中间型和阳性病例在无细胞白血病和前B细胞白血病中分布相对均匀，有1例中间型和2例阳性T细胞病例。2例B细胞白血病中有1例也为阳性。没有可区分FcR阳性病例的独特临床或实验室特征，在ALL整体或免疫定义的表型中，FcR也没有预后意义。
